Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Metadata
Title
Castration-resistant metastatic prostate cancer: current status and treatment possibilities
Authors
Joan Carles
Daniel Castellano
Miguel Ángel Climent
Pablo Maroto
Rafael Medina
Antonio Alcaraz
Publication date
01-03-2012
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2012
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0780-8

Other articles of this Issue 3/2012

Clinical and Translational Oncology 3/2012 Go to the issue

Research Articles

Evaluation of ER-α, ER-β1 and ER-β2 expression and correlation with clinicopathologic factors in invasive luminal subtype breast cancers

Research Articles

Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients

Research Articles

PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation

Research Articles

Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians

Research Articles

Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients

Research Articles

Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits